Home > Dermatology > EADV 2020 > Late-Breaking News > Promising results with nanobody treatment in psoriasis

Promising results with nanobody treatment in psoriasis

Presented By
Dr Kim A. Papp, Probity Medical Research, Canada
Conference
EADV 2020
Trial
Phase 2
A phase 2b trial showed significant and clinically meaningful benefits of sonelokinab compared with placebo in moderate-to-severe chronic plaque psoriasis. “Sonelokinab is a trivalent camelid nanobody comprised of 2 active elements, an IL-17F moiety and an IL-17A/F moiety, bound to albumin as central moiety. Binding with albumin prolongs the half-life to 10-12 days,” explained Dr Kim A. Papp (Probity Medical Research, Canada) [1]. The multicentre, double-blind, phase 2b trial investigated the efficacy and safety of sonelokinab (formerly known as M1095) in the treatment of moderate-to-severe chronic plaque psoriasis. Participants (n=313) were randomised into 6 arms: 3 groups received sonelokinab subcutaneously at doses 30 mg, 60 mg, and 120 mg (at weeks 0, 2, 4, and subsequently every 4 weeks); 1 group received an enhanced loading dose of sonelokinab 120 mg every 2 weeks through to week 12; 1 group received a placebo; and 1 group received s...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on